Stocks · News reference
Top analysts changed outlook on top names. For all changes, see analyst ratings page. See how analysts view HOOD, FXNC, NU, FTH, FRST.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-31 AccNo: 0001104659-26-103947 Size: 183 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.
Bitcoin jumped 22% in August as gold correlation hit a six-year high. Analysts say shifting links may aid diversification as Wall Street adopts blockchain.
Robinhood Chain is seeing a surge in metrics, which is helping fuel the Arbitrum ARB token, which has soared to its highest point since January.